Skip to main content

Table 3 Multivariate analysis

From: Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study

Time Risk factor RR p-value
First six months period day 0–182 since first R dose Nadir ≥0.13 ×109 /L 1.00  
Nadir <0.13 ×109 /L 1.89 (1.00-3.60) 0.051
HIV neg. 1.00  
HIV pos. 2.92 (1.11-7.65) 0.030
no GVHD 1.00  
GVHD 1.49 (0.52-4.27) 0.453
Indolent lymphoma 1.00  
Aggressive lymphoma 2.76 (1.34-5.670 0.006
Non-CD20 malignancy 1.56 (0.56-4.33) 0.394
Second six months period day 183–364 since first R dose Nadir ≥0.13 ×109 /L 1.00  
Nadir <0.13 ×109 /L 2.68 (1.19-6.04) 0.017
HIV neg. 1.00  
HIV pos. 1.21 (0.27-5.38) 0.798
no GVHD 1.00  
GVHD 7.22 (2.38-21.92) <0.001
Indolent lymphoma 1.00  
Aggressive lymphoma 1.21 (0.48-3.02) 0.687
Non-CD20 malignancy 1.57 (0.49-4.98) 0.447
Third six months period day 364–546 since first R dose Nadir ≥0.13 ×109 /L 1.00  
Nadir <0.13 ×109 /L 2.54 (1.07-6.02) 0.034
HIV neg. 1.00  
HIV pos. 1.49 (0.33-6.67) 0.601
no GVHD 1.00  
GVHD 3.65 (1.11-12.04) 0.034
Indolent lymphoma 1.00  
Aggressive lymphoma 1.53 (0.60-3.91) 0.371
Non-CD20 malignancy 0.93 (0.25-3.42) 0.908
  1. The model allows interaction with time since first Rituximab administration and each risk factor. The analysis provides moderate to strong evidence that all the 4 risk factors were associated with the infections in a time dependent manner; i.e.: HIV and type of diagnosis were associated with increased risk of infection in first six months only, GVHD in the second and third time periods while counts of lymphocytes at nadir was associated with increased risk for all the 3 time periods.
  2. HSCT hematopoietic stem cell transplant, HIV antibody against human immunodeficiency virus, GVHD graft versus host disease, R Rituximab, CHT chemotherapy, IQR inter-quartile range, RR rate ratio, 95%CI 95% confidence interval.